Multibagger Ideas is one of the few newsletters I read every week. Nico started it a few months before we launched Rebound Capital, and consistent, high-quality research has taken it close to 40,000 subscribers.
As the name suggests, he hunts the market’s biggest winners: small companies, high returns on capital, owner-operators, long runways to reinvest, and a sensible entry price. Most are small and micro caps no institution can own, and no analyst covers.
Today’s guest post is about Eton Pharmaceuticals (ETON). Nico first covered it in November 2025, mid-drawdown. It is now the largest position in his Model Portfolio, up 247%.
He also put together a special discount for Rebound Capital readers.
Multibaggers Spend Their Lives in Drawdown
Rebound Capital is based on the premise that great businesses go on sale more often than people think.
Multibagger Ideas is based on a slightly longer-dated version of the same premise.
The stocks that eventually deliver huge returns spend most of their lives being sold by somebody.
The strongest proof I know of on that subject comes from Alta Fox Capital.
In 2020, they ran a screen on all the stocks in North America, Western Europe and Australia that had returned more than 350% over the last five years. 104 stocks made the cut.
Then they dissected each one, trying to allocate the return between multiples and EBITDA growth.
For the median multibagger, multiples explained roughly two-thirds of the total return. EBITDA growth explained about a third.
The same study yields two other interesting conclusions.
84% of the multibaggers had market cap under $2bn when the clock started ticking.
82% of them were trading at less than 3x sales, 20x EBITDA or 30x earnings. Not cheap value. Just not expensive.
Combine those facts, and you’ll get the picture.
A small company, valued as if not much is expected from it, sitting in front of a market that hasn’t made up its mind about it yet. Multiples do the rest.
That’s why drawdowns matter, and why Rebound Capital is such a great page to follow.
This week’s post is about a stock that lost 36% in 4 months while nothing happened, and gained 4x in the subsequent 6 months where everything did.
The Drawdown
Eton Pharmaceuticals peaked on 29 September 2025.
It touched its lows on 5 February 2026, falling $8.13, or 36.17%.
I covered the company on 14 November 2025 at $16.92, a little more than a week after the Q3 report that took the stock down by around 12%.
I was too early.
The stock fell another 15% after my coverage before it turned.
I cannot provide you with a satisfying reason for the fall of the stock by 36%.
One quarterly earnings report on 6 November, two investor conferences, and one licensing agreement on 2 February. No capital raise. No FDA rejection. No guidance reduction. At the same Q3 report, the company reaffirmed its guidance for the full year revenues of $82-$84m, which represented an increase of more than 60% y/y.
The only thing I can say is that it was likely optics.
Q3 adjusted gross margin came in at 45% against 70% the company normally reports. This was due to some one-time expenses related to the transfer of INCRELEX distribution rights outside the US.
Without the footnote, you see the margin problem.
With the footnote, you see the expenses that the company used to report as non-recurring, and which were expected to fall in Q4 and cease by mid-2026. (And that is precisely what happened).
Aside from that, you had a good business doing something unique and doing it exceptionally well.
Eton acquires US rights to rare disease medicines that are too niche for large pharmaceutical companies to bother with, passes them through the specialist sales force they already paid for, and recovers most of their investment. At that point in time, the company had posted 19(!!) quarters of sequential revenue growth, posted gross margins in the low seventies, turned cash flow positive, and with an FDA decision due in February.
Mr. Market was either not interested or simply too preoccupied with a margin drop that the company had already addressed!
The company continued to perform regardless.
The FDA approval came through, followed by product launch. Another product was acquired and relaunched. Guidance was raised two times. (You can check out the entire timeline on my page)
At some point in there, the market realized it was time for re-rating, and here we are today.
As of writing, the 20th of August, the stock trades around $61.48.
This represents an increase of 263.36% since my coverage began and more than 4x since the February low.
The rest of this post is about what the company actually does, why I think it deserved better than the Feb low, and where I think it goes from here…
How Eton Makes Money
Eton obtains licenses or acquires US rights to rare disease medicines and distributes them through its commercial network.
As of Q2 2026, Eton holds eleven commercial products: INCRELEX, HEMANGEOL, ALKINDI SPRINKLE, KHINDIVI, DESMODA, GALZIN, PKU GOLIKE, IMPAVIDO, carglumic acid, betaine anhydrous, and nitisinone.
Eleven commercial products and six in development, divided among the three groups of prescribers Eton sells to. Eight out of eleven were acquisitions or licenses, not discoveries.
The company's revenue model is pretty simple. Eton sells product to specialty pharmacy distributors, principally AnovoRx, and books revenue when inventory is pulled and shipped against a specific patient prescription.
It books net revenue, not list price. Out of the billed price come co-pay support, Medicaid and government rebates, chargebacks and prompt payment discounts. That trade-off sits at the center of the model. Eton runs $0 co-pay programs on most products, which costs realized price and buys patient volume and persistence.
Eton reported net product sales of $37.6m in Q2 2026, up 99% year on year.
Below the revenue line, Eton pays for finished product from third-party manufacturers, logistics, royalties and profit shares to the owners of the rights, and amortization of acquired product rights. What is left is gross profit: $25.4m in Q2, a 73% adjusted gross margin.
The royalties are worth spelling out, because they are the real cost of the model and nobody really talks about them:
HEMANGEOL: $14m paid upfront for the right to the product in the US, plus 8% of the net sales as royalty until expiration of the patent in October 2028
ALKINDI SPRINKLE and KHINDIVI: tiered royalties between 11% and 17% of net sales
DESMODA: tiered royalties of 12.5% to 17%
GALZIN: 10% of net sales in the US until the tenth anniversary of the first commercial sale
IMPAVIDO: distribution agreement. Eton pays Knight 55% of the net sales up to $7m and 50% above, but Eton does not have the cost of manufacturing and all the regulatory costs. Eton covers sales and marketing cost
ASN-001, if approved: 10% of the cumulative lifetime sales until $200m, 13% of the cumulative lifetime sales between $200m and $400m, 15% of the cumulative lifetime sales above
So Eton does not earn 73% of every dollar perpetually. It pays somebody else’s royalty, and therefore the next thing to think about is how expensive is it to generate that margin.
The Economics
During Q2, the company generated $25.4m of gross profit. The company incurred $1.0m of R&D expenses and $11.6m of G&A expenses. As a result, the company earned $12.8m of operating income, $11.6m of GAAP net income, and $16.2m of adjusted EBITDA, which is equal to a 43% margin.
Q2 the year before, the business reported $18.9m of revenue and a 16% adjusted EBITDA margin.
Revenue doubled. G&A expenses increased 20%.
This is how the whole model looks in two numbers, and there is a clear reason it works.
Eton has 20 sales specialists organized in three teams and targeting 3,600 physician targets. 11 of them target pediatric endocrinology, five target metabolics, and four target pediatric dermatology. This is the entire commercial infrastructure of the business, which is about to generate more than $145m of revenue.
These teams work effectively thanks to the lack of movement of the prescriber base between products. At the launch of DESMODA, the management estimated the overlap with the existing ALKINDI SPRINKLE, KHINDIVI and INCRELEX prescriber base at 97%. Same doctors.
Thus, when Eton acquires a new product, its incremental gross profit turns into operating income without any incremental expenses.
It has now built three of these call points, and each one is a shelf that new products can be placed on.
Twenty sales specialists across three teams, and the products each one carries. New acquisitions get slotted onto an existing shelf rather than requiring a new one.
Much remains to be done with regard to these products that Eton has. According to the company’s internal statistics, the penetration of ALKINDI SPRINKLE and KHINDIVI in their target audience of 5,000 people is estimated at 12%. The penetration rate of GALZIN among about 800 Wilson disease patients using zinc treatment is estimated at 38%. DESMODA, which was introduced in March, stands at 0%.
Penetration of the four largest products against the patient populations Eton is targeting. Three of the four are still in single or low double digits.
Purchasing products comes at a cost. Most companies following this strategy do so through equity or debt. However, Eton has financed its purchases with cash from the business.
During the first half of 2026, it incurred a cost of $15m on product rights, voluntarily paid off $3m of debt, and booked a $13.1m increase in receivables, due to the doubling of revenue. The operating cash flow of $14.7m financed all of it.
Two acquisitions, a full product relaunch, and cash, saw the company end the half at $26.8m compared to its beginning cash balance of $25.9m.
Equity financing was not used; nor was there any new borrowing. Its total debt stands at $27.9m against $26.8m of cash.
“But many rollups tend to fail.”
They do, and that is the right objection. However, this is also the one I would most argue against, and for two reasons.
First, deal structure.
Every deal Eton has ever done has been small, cash-financed, and contingent on cost rather than up-front cost. HEMANGEOL cost $14 million in cash but now carries an 8% royalty on whatever it sells. ASN-001 cost $3 million in cash up front but pays 10% to 15% only if it is approved and on whatever it makes. IMPAVIDO cost virtually nothing: Knight owns the economics and bears the cost of the product and regulatory process.
The typical roll-up failure is the big deal that is financed either through equity or leverage and is priced on Day One based on assumed synergies. Eton has been doing the opposite. It has paid little up front and the vast majority of its payments have been contingent on success. In the event of poor performance, the royalty decreases along with it.
Second, the machine has now worked three times in nine months.
Product sales by year. $3m in 2021 to more than $145m guided for 2026, built almost entirely from products other companies had given up on.
Nine months ago, it was a $453 million business with eight commercial products and a pending FDA decision. In the meantime, Eton has taken DESMODA from approval to launch, acquired HEMANGEOL for $14 million and made it the company’s largest product, migrated around 8,000 patients from eighteen different pharmacies to one channel ahead of schedule, licensed the next-generation asset of the franchise, acquired IMPAVIDO, filed for a label expansion of KHINDIVI, got a Fast Track designation for AMGLIDIA, and started two clinical trials.
It accomplished all of that while increasing the adjusted EBITDA margin from 16% to 43%, without issuing any stock.
This is not a market reaction to one strong quarter. This is a market reaction to the realization that this is a repeatable process, not a lucky streak of transactions.
Here is where I might be conceding something: every deal so far has been small. On the Q2 call, CEO Sean Brynjelsen noted that profitability increase has “expanded our financial capacity, allowing us to pursue a broader range of transactions, including potentially larger opportunities.” Larger deals are where rollups fail. The system has been proven with $3 million to $14 million deals. It has not been proven with $100 million deals.
Where The $500m Comes From
The management aims to achieve $500m in revenues by 2030 compared to the $145m that we have today.
In the slides, the management has divided the gap into three components, but it is important to note how many of those depend on things that do not exist today.
$200m+ from products currently available on the market. ALKINDI SPRINKLE, KHINDIVI, HEMANGEOL, GALZIN, INCRELEX, carglumic acid and DESMODA, at 100% penetration of the above populations.
$150m+ from two label extensions. INCRELEX harmonization study, KHINDIVI label extension to infants less than four years old. None requires a new product, both require FDA approval.
$250m+ from the pipeline. ET-700 more than $100m, ET-800 more than $100m, ZENEO more than $100m, AMGLIDIA $10m to $30m.
Mergers and acquisitions on top, tagged as TBD, with a target of two per year.
Management’s own build of the $500m target, split between existing products, label expansions and pipeline, before any further acquisitions.
Read it with the proper grains of salt.
Peak sales is the most optimistic figure in the pharmaceutical business. It does not come with any date or probability weighting and discounting rate and the pipeline layer has two products which have not gone through the pivotal phase. If you read the figures literally, you will see that the 2030 target has been met twice by now, which is precisely what this kind of slide is intended to show you.
What I do believe is the bottom layer.
Over 200 million dollars worth of revenues from products that Eton is selling right now in the patient population it has published and is currently converting at the rate given in the previous section, takes you a long way towards meeting the 2030 target by itself.
All the rest is just a bonus.
Where the valuation sits now
Eton is valued at around $1.7 billion at a price of $61.48. The balance between cash and debt is almost neutral, making the enterprise value similar.
Comparing this with the annual guidance for a revenue of more than $145 million and an adjusted EBITDA margin of 35%, the multiple is around 33x EBITDA.
Revenue against adjusted SG&A on the left, and the margin path management is guiding to on the right. Adjusted EBITDA margin went from 7% in 2024 to 20% in 2025, with more than 35% guided this year and 50% targeted for 2028.
Management has three stated objectives:
Exit at $200m revenue run rate in 2027. On the Q2 call Brynjelsen said Eton is “well ahead of this goal”
50% adjusted EBITDA margin in 2028. They printed 43% in Q2, in a quarter that included a brand new launch
$500m of annual revenue by 2030, which management now says it expects to achieve or exceed with ASN-001 added
Take the first two at face value and you end up with $100m of adjusted EBITDA.
Today’s enterprise value is 17x that number.
So the honest appraisal of the last nine months is that the re-rating is done. In November you were paying about 9x the adjusted EBITDA the company now expects to generate this year. At the February low you were paying about 7.5x. Today you are paying 33x.
This is the gap that gets plugged. It is the two thirds of the return that Alta Fox found in the median winner.
But a completed re-rating is not the same thing as a completed run.
The greatest winners in market history kept going long after the cheapness had gone away.
Monster and Netflix were not cheap for most of their compounding.
What carried them was the earnings that kept arriving faster than the market had expected.
Which is where I believe Eton is now.
The forward numbers are still growing faster than the stock price. Q2 revenue annualises to $150m against a 2027 exit target of $200m that management says it is already ahead of. Margins are coming in ahead of the 2028 schedule by eight points. And the two assets management believes will be the largest in the portfolio, ASN-001 and ET-700, are contributing nothing at all to current revenue.
I have owned this since November and it is the largest holding in my Model Portfolio at roughly 12%. I have not reduced it.
The two things I am keeping an eye on are the ET-700 pilot, which is weeks away, and the Q3 HEMANGEOL number, which will be the first clear reading on the biggest revenue line in the business.
I will write about both of those when they happen.
The broader point I would leave with the Rebound Capital reader is the one above.
The drawdown that allowed this purchase lasted four months, hit 36%, and had no news worth speaking of. I could not identify a catalyst at the bottom because there was none to identify. What was there was a company generating more money each quarter while its stock price fell, and a market cap low enough that nobody who has access to a Bloomberg terminal cares.
This is the whole deal.
Risks
HEMANGEOL patent cliff of 2028: Largest product loses patent in October 2028. Replacement for HEMANGEOL is ASN-001, launched in same year. Transition must be seamless, and it got 90 seconds on a 50-minute call.
Q3 is the first clean read: Q2 was a transition quarter with channel noise in it. Sequential growth in HEMANGEOL sales is necessary to prove that the run rate assumed now is right.
ET-700 could fail: Pilot results will come within weeks. Negative results rule out a program with management sizes above $100 million peak US sales.
Concentration risk: Anovorx was 90.4% of first-half product revenue and 88.1% of receivables. Receivables more than doubled to $24.9 million, which is about 66% of quarterly revenues. Rapid growth explains some of it. It won’t explain it twice.
A GAAP surprise is coming: Eton may announce a $22 million deferred tax valuation allowance this year. If a huge EPS number comes in Q4 or Q1, it’s because of an accounting entry. Adjusted EBITDA is the real number.
Deal size: Discipline proven at $14 million is not discipline proven at $140 million.
I hope you enjoyed today’s post.
If you would like to read more about companies just like Eton, you can upgrade to Multibagger Ideas here at a discounted price:
Thanks for reading,
Nico
Disclaimer: The Content does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Nothing in this newsletter should be construed as a personal recommendation or advice to buy, sell, or hold any investment or security. All Content is provided for general informational purposes only and should not be relied upon for making investment decisions. You should not make any investment decision based solely on the Content without first consulting with qualified financial advisors, conducting your own research, and considering your individual financial circumstances, investment objectives, and risk tolerance. To read our full disclaimer, click here.